Share：
Share this content in WeChat
X
[Chinese][PDF]681545
• Review •
The progress of diffusion-weighted MRI application in prostate cancer diagnosis
Sutedjo Janesya  CHEN Hui-You  JIANG Liang  WANG Li-Wei  YIN Xin-Dao 

Hui-you to make the same contribution to this work DOI:10.3969/j.issn.1674-8034.2015.05.016.


[Abstract] Magnetic resonance imaging (MRI) has been used in prostate cancer (PCa) diagnosis for over a decade. Diffusion weighted imaging (DWI) is one of the methods of the MRI techniques that could provide qualitative as well as quantitative information at a cellular level. DWI potentially could develop into a powerful technique to improve the accuracy of MRI to evaluate the PCa. In this article, we will present the basics of DWI, clinical application, as well as the limitations and the future directions of DWI of PCa.
[Keywords] Prostatic neoplasms；Diffusion magnetic resonance imaging；Review literature as topic

Sutedjo Janesya Department of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China

CHEN Hui-You The Third Clinical Medicine School of Nanjing Medical University, Nanjing 210029, China Janesya Sutedjo and Chen

JIANG Liang Department of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China

WANG Li-Wei* The Third Clinical Medicine School of Nanjing Medical University, Nanjing 210029, China Janesya Sutedjo and Chen

YIN Xin-Dao* Department of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China

*Correspondence to: Yin XD, E-mail: y.163yy@163.com Wang LW, E-mail: wangliwei_ nanjing@163.com

Conflicts of interest   None.

Received  2015-02-09
Accepted  2015-04-10
DOI: 10.3969/j.issn.1674-8034.2015.05.016
Hui-you to make the same contribution to this work DOI:10.3969/j.issn.1674-8034.2015.05.016.

[1]
Stewart BW, Wild CP. World cancer report 2014. France: International Agency for Research on Cancer, 2014: 453-454.
[2]
Aydin H, Kizilgoz V, Tatar IG, et al. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings. J Comput Assist Tomogr, 2012, 36(1): 30-45.
[3]
Lim KS, Tan CH. Diffusion-weighted MRI of adult male pelvic cancers. Clin Radiol, 2012, 67(9): 899-908.
[4]
Yagci AB, Ozari N, Aybek Z, et al. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Interv Radiol, 2011, 17(2): 130-134.
[5]
AbdelMaboud NM, Elsaid HH, Aboubeih EA. The role of diffusion: weighted MRI in evaluation of prostate cancer. Egyp J Radiol Nucl Med, 2014, 45(1): 231-236.
[6]
Hekimoğlu B, Aydin H, Kızılgöz V, et al. Identification and localization of prostate cancer with combined use of T2-weighted, diffusion weighted MRI and proton MR spectroscopy, correlation with histopathology. Adv J Mol Imaging, 2013, 3(3): 23-36.
[7]
Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology, 2011, 261(1): 46-66.
[8]
Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol, 2007, 189(2): 323-328.
[9]
Morani AC, Elsayes KM, Liu PS, et al. Abdominal applications of diffusion-weighted magnetic resonance imaging: where do we stand. World J Radiol, 2013, 5(3): 68-80.
[10]
Kim CK, Park BK, Kim B. Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. AJR Am J Roentgenol, 2010, 194(6): 1461-1469.
[11]
Wang X, Qian Y, Liu B, et al. High-b-value diffusion-weighted MRI for the detection of prostate cancer at 3 T. Clin Radiol, 2014, 69(11): 1165-1170.
[12]
Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol, 2007, 188(6): 1622-1635.
[13]
Thormer G, Otto J, Reiss-Zimmermann M, et al. Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol, 2012, 22(8): 1820-1828.
[14]
Kwee TC, Takahara T, Ochiai R, et al. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol, 2008, 18(9): 1937-1952.
[15]
Kele PG, van der Jagt EJ. Diffusion weighted imaging in the liver. World J Gastroenterol, 2010, 16(13): 1567-1576.
[16]
Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia, 2009, 11(2): 102-125.
[17]
Kim CK, Park BK, Lee HM, et al. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol, 2007, 42(12): 842-847.
[18]
Petralia G, Thoeny HC. DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging, 2010, 10(1A): S112-S123.
[19]
Yamamura J, Salomon G, Buchert R, et al. MR imaging of prostate cancer: diffusion weighted imaging and (3D) hydrogen 1 (H) MR spectroscopy in comparison with histology. Radiol Res Pract, 2011, 2011: 616852.
[20]
Liu X, Peng W, Zhou L, et al. Biexponential apparent diffusion coefficients values in the prostate: comparison among normal tissue, prostate cancer, benign prostatic hyperplasia and prostatitis. Korean J Radiol, 2013, 14(2): 222-232.
[21]
Kim CK, Park BK, Han JJ, et al. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. J Comput Assist Tomogr, 2007, 31(3): 449-454.
[22]
Reinsberg SA, Payne GS, Riches SF, et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol, 2007, 188(1): 91-98.
[23]
Kitajima K, Kaji Y, Kuroda K, et al. High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-to-noise ratio. Magn Reson Med Sci, 2008, 7(2): 93-99.
[24]
Wang XZ, Wang B, Gao ZQ, et al. Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging, 2009, 29(6): 1360-1366.
[25]
Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. Radiology, 2008, 246(2): 480-488.
[26]
Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol, 2006, 41(2): 185-188.
[27]
Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging, 2002, 16(2): 196-200.
[28]
Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging, 2005, 21(3): 258-262.
[29]
Kim JH, Kim JK, Park BW, et al. Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging, 2008, 28(5): 1173-1179.
[30]
Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol, 2009, 44(9): 572-576.
[31]
Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU international, 2009, 103(7): 883-888.
[32]
desouza NM, Reinsberg SA, Scurr ED, et al. Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol, 2007, 80(950): 90-95.
[33]
Tanimoto A, Nakashima J, Kohno H, et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging, 2007, 25(1): 146-152.
[34]
王利伟，王牧，王绍娟，等. MR扩散加权成像诊断前列腺癌的价值分析．磁共振成像, 2014, 5(3): 198-201.
[35]
Kilickesmez O, Cimilli T, Inci E, et al. Diffusion-weighted MRI of urinary bladder and prostate cancers. Diagn Interv Radiol, 2009, 15(2): 104-110.
[36]
Simpkin CJ, Morgan VA, Giles SL, et al. Relationship between T2 relaxation and apparent diffusion coefficient in malignant and non-malignant prostate regions and the effect of peripheral zone fractional volume. Br J Radiol, 2013, 86(1024): 20120469.
[37]
Metens T, Miranda D, Absil J, et al. What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3 T?Eur Radiol, 2012, 22(3): 703-709.
[38]
Kitajima K, Takahashi S, Ueno Y, et al. Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high b-value (2000 s/mm) and standard high b-value (1000 s/mm). J Magn Reson Imaging, 2012, 36(1): 198-205.
[39]
Riches SF, Hawtin K, Charles-Edwards EM, et al. Diffusion-weighted imaging of the prostate and rectal wall: comparison of biexponential and monoexponential modelled diffusion and associated perfusion coefficients. NMR Biomed, 2009, 22(3): 318-325.
[40]
Shinmoto H, Oshio K, Tanimoto A, et al. Biexponential apparent diffusion coefficients in prostate cancer. Magn Reson Imaging, 2009, 27(3): 355-359.
[41]
Katahira K, Takahara T, Kwee TC, et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol, 2011, 21(1): 188-196.
[42]
Rosenkrantz AB, Hindman N, Lim RP, et al. Diffusion-weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection. J Magn Reson Imaging, 2013, 38(3): 694-700.
[43]
Le Bihan D, Breton E, Lallemand D, et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology, 1988, 168(2): 497-505.
[44]
Shinmoto H, Tamura C, Soga S, et al. An intravoxel incoherent motion diffusion-weighted imaging study of prostate cancer. AJR Am J Roentgenol, 2012, 199(4): W496-W500.
[45]
Dopfert J, Lemke A, Weidner A, et al. Investigation of prostate cancer using diffusion-weighted intravoxel incoherent motion imaging. Magn Reson Imaging, 2011, 29(8): 1053-1058.
[46]
Takahara T, Imai Y, Yamashita T, et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med, 2004, 22(4): 275-282.
[47]
龚佳英，周智洋，邓艳红，等. MR全身扩散加权成像技术在肿瘤病变中的应用价值．磁共振成像, 2013, 4(6): 420-425.
[48]
Murtz P, Krautmacher C, Traber F, et al. Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla. Eur Radiol, 2007, 17(12): 3031-3037.
[49]
Gurses B, Kabakci N, Kovanlikaya A, et al. Diffusion tensor imaging of the normal prostate at 3 Tesla. Eur Radiol, 2008, 18(4): 716-721.
[50]
王倩，房俊芳，王滨．磁共振扩散张量成像诊断前列腺癌的理论基础．磁共振成像, 2015, 6(1): 76-80.

PREV Development and application of new MRI technology in rectal cancer
NEXT An expectable wave of clinical studies using quantitative dynamic contrast-enhanced MR imaging
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn